Background: Intrauterine Growth Restriction (IUGR) is a challenging condition associated with adverse perinatal outcomes. Sildenafil Citrate, a phosphodiesterase type 5 inhibitor known for its vasodilatory effects, has been promising in improving uteroplacental perfusion. This prospective case-control study aims to investigate the impact of Sildenafil Citrate on IUGR, evaluating its potential as a therapeutic intervention. Objective: The primary objective of this study is to determine whether the use of Sildenafil Citrate improves uteroplacental perfusion and fetal growth in pregnancies complicated by IUGR. This study also includes evaluating neonatal outcomes, and the overall feasibility of Sildenafil as a treatment option. Methods: This study involves 50 pregnant women, gestational age between 25-37 weeks, diagnosed with IUGR, randomly assigned into two equal groups: a treatment group A administered orally with 50 mg Sildenafil Citrate per day and another treatment group B administered Sildenafil Citrate. Uteroplacental perfusion was assessed through Doppler ultrasound measurements, and fetal growth parameters were monitored using standard ultrasound techniques. Maternal and neonatal outcomes, including adverse effects, were also documented. Results: The mean age of patients in group A was 29±5.2 years and group B was 28±4.5 years. Umbilical artery Doppler index significantly improved in sildenafil treated group compared to the control group. There was a significant difference in the mean gestational age at delivery in treatment group A compared to the group B (p value= 0.03). Birth weight in neonates of treated participants was significantly higher as compared to the control group (p <0.001). A significant reduction in NICU admission was found in the new-borns in Sildenafil Citrate treated participant. There was no significant difference in the pregnancy outcomes related to oligohydramnios in both study groups. Conclusion: Sildenafil Citrate is effective in extending the gestation to allow increased birth weight in patients diagnosed with IUGR. Administration of Sildenafil Citrate also reduces the admission of neonates to NICU.